Clinical Trial Detail

NCT ID NCT02775851
Title Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

malignant spindle cell melanoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.